Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 10 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

10Total
Not Applicable (2)
Early P 1 (1)
P 1 (6)
P 2 (1)

Trial Status

Recruiting4
Unknown2
Not Yet Recruiting2
Active Not Recruiting1
Withdrawn1

Clinical Trials (10)

Showing 10 of 10 trials
NCT07523542Phase 1RecruitingPrimary

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

NCT06530849Phase 1RecruitingPrimary

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

NCT07432334Phase 1Not Yet RecruitingPrimary

CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

NCT06265220Phase 1Active Not Recruiting

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06513429Not ApplicableRecruitingPrimary

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

NCT07083349Not ApplicableNot Yet RecruitingPrimary

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

NCT06676631Phase 1RecruitingPrimary

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

NCT05063513Phase 2WithdrawnPrimary

Autologous Stem Cell Transplantation: International Lupus Trial

NCT05930314Early Phase 1UnknownPrimary

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

NCT00698191Phase 1UnknownPrimary

Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)

Showing all 10 trials

Research Network

Activity Timeline